Ken Ohmachi
Impact in
-
- Lymphoma Diagnosis and Treatment
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 28
- Oncology 23
- Viral-associated cancers and disorders 9
- CAR-T cell therapy research 4
- Cancer Treatment and Pharmacology 3
- Co-authors
- Kiyoshi Ando (33 shared papers)Michinori Ogura (19 shared papers)Kensei Tobinai (14 shared papers)Toshiki Uchida (12 shared papers)Yoshiaki Ogawa (17 shared papers)Hiroshi Kawada (13 shared papers)Naokuni Uike (5 shared papers)Naoya Nakamura (10 shared papers)
- Journals
- Blood (9 papers)International Journal of Hematology (9 papers)Cancer Science (6 papers)Journal of Clinical and Experimental Hematopathology (3 papers)Annals of Hematology (3 papers)
- Partner nations
- JapanUnited StatesGreece
In The Last Decade
Ken Ohmachi
47 papers receiving 679 citations
Peers
Comparison fields: 5 of 56
- Pathology and Forensic Medicine 398
- Genetics 212
- Oncology 312
- Hematology 90
- Neurology 101
Countries citing papers authored by Ken Ohmachi
This map shows the geographic impact of Ken Ohmachi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Ohmachi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Ohmachi more than expected).
Fields of papers citing papers by Ken Ohmachi
This network shows the impact of papers produced by Ken Ohmachi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Ohmachi. The network helps show where Ken Ohmachi may publish in the future.
Co-authors
The 25 scholars most cited alongside Ken Ohmachi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 | 121 | |
| 2 | 2014 | 58 | |
| 3 | 2010 | 52 | |
| 4 | 2019 | 48 | |
| 5 | 2015 | 36 | |
| 6 | 2003 | 33 | |
| 7 | 2010 | 29 | |
| 8 | 2019 | 28 | |
| 9 | 2018 | 25 | |
| 10 | 2011 | 25 | |
| 11 | 2017 | 21 | |
| 12 | 2017 | 21 | |
| 13 | 2011 | 19 | |
| 14 | 2015 | 16 | |
| 15 | Phase I Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin's Lymphoma. | 2014 | 15 |
| 16 | 2015 | 12 | |
| 17 | 2015 | 12 | |
| 18 | 2022 | 11 | |
| 19 | 2020 | 11 | |
| 20 | 2022 | 10 |
About Ken Ohmachi
Ken Ohmachi is a scholar working on Pathology and Forensic Medicine, Oncology, Hematology, Genetics and Neurology, having authored 50 papers that have together received 690 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (28 papers), Chronic Lymphocytic Leukemia Research (13 papers), Viral-associated cancers and disorders (9 papers), CNS Lymphoma Diagnosis and Treatment (8 papers), Multiple Myeloma Research and Treatments (7 papers), Chronic Myeloid Leukemia Treatments (5 papers), CAR-T cell therapy research (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (398 citations), Genetics (212 citations), Oncology (312 citations), Hematology (90 citations) and Neurology (101 citations). Ken Ohmachi has collaborated with scholars based in Japan, United States and Greece. Frequent co-authors include Kiyoshi Ando, Michinori Ogura, Kensei Tobinai, Toshiki Uchida, Yoshiaki Ogawa, Hiroshi Kawada, Naokuni Uike, Naoya Nakamura, Yukari Shirasugi and Nozomi Niitsu. Their work appears in journals such as Blood, International Journal of Hematology, Cancer Science, Journal of Clinical and Experimental Hematopathology and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.